Here are three updates on GI companies from the past week:
The National Institute for Health and Care Excellence recommended Allergan's Truberzi for irritable bowel syndrome with diarrhea, making it the first such treatment to be recommended for use by the agency.
Takeda CEO Christophe Weber reaffirmed the company's commitment to globalizing its brand and products amid struggling fiscal year 2017 sales.
Commonwealth Diagnostics relaunched its U.S.-based gastroenterology diagnostic testing business.
More article on gastroenterology:
Stock market week-in-review for 5 large GI companies — Aug. 28-Sept. 1
GI leader to know: Dr. Mark Cossentino of Endoscopy Center of El Paso
GI center to know: Endoscopy Center of El Paso